Cite

HARVARD Citation

    Molica, S. et al. (2022). Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia. Leukemia & lymphoma. 63 (8), pp. 1771-1773. [Online]. 
  
Back to record